(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
This Week In Space podcast: Episode 204 — A New NASA - 2Instructions to Keep an Inspirational perspective After Cellular breakdown in the lungs Treatment
- 3German mid-sized firms gloomy on outlook, survey finds
- 4Thousands of genomes reveal the wild wolf genes in most dogs’ DNA
- 5Ageless Tastefulness: An Outline of Valuable Gemstones and Adornments
- Surging measles cases are 'fire alarm' warning that other diseases could be next
- Dominating Your Cash: The Fundamental Manual for Overseeing Individual accounting records
- Embrace the Outside: Exercises and Entertainment
- Mechanical Sidekick d: A Survey of \Elements and Execution d\ Cell phone
- CRP Subsea secures contract for Vattenfall’s Nordlicht I cable systems
- 'Every day I planned an escape': Ariel Cunio shares details of Hamas captivity
- Instructions to Utilize Your Brain science Certification to Work on Corporate Culture
- 2025 among world's three hottest years on record, WMO says
- WHO issues guidance on GLP-1 drugs for obesity
